• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Blood Cells Mol Dis . γ' fibrinogen levels as a biomarker of COVID-19 respiratory disease severity

tetano

Editor, Senior Moderator
Blood Cells Mol Dis


. 2023 Apr 28;102746.
doi: 10.1016/j.bcmd.2023.102746. Online ahead of print. γ' fibrinogen levels as a biomarker of COVID-19 respiratory disease severity

Lucy Z Kornblith[SUP] 1 [/SUP], Bindhya Sadhanandhan[SUP] 2 [/SUP], Sreepriya Arun[SUP] 2 [/SUP], Rebecca Long[SUP] 3 [/SUP], Alicia J Johnson[SUP] 4 [/SUP], Jamie Noll[SUP] 5 [/SUP], C N Ramchand[SUP] 6 [/SUP], John K Olynyk[SUP] 7 [/SUP], David H Farrell[SUP] 8 [/SUP]



Affiliations
Abstract

Coronavirus disease 2019 (COVID-19) is characterized by a pro-inflammatory state associated with organ failure, thrombosis, and death. We investigated a novel inflammatory biomarker, γ' fibrinogen (GPF), in 103 hospitalized patients with COVID-19 and 19 healthy controls. We found significant associations between GPF levels and the severity of COVID-19 as judged by blood oxygen saturation (SpO[SUB]2[/SUB]). The mean level of GPF in the patients with COVID-19 was significantly higher than in controls (69.8 (95 % CI 64.8-74.8) mg/dL compared with 36.9 (95 % CI 31.4-42.4) mg/dL, p < 0.0001), whereas C-reactive protein (CRP), lactate dehydrogenase (LDH), and total fibrinogen levels were not significantly different between groups. Mean GPF levels were significantly highest in patients with severe COVID-19 (SpO[SUB]2[/SUB] ≤ 93 %, GPF 75.2 (95 % CI 68.7-81.8) mg/dL), compared to mild/moderate COVID-19 (SpO[SUB]2[/SUB] > 93 %, GPF 62.5 (95 % CI 55.0-70.0) mg/dL, p = 0.01, AUC of 0.68, 95 % CI 0.57-0.78; Youden's index cutpoint 62.9 mg/dL, sensitivity 0.64, specificity 0.63). In contrast, CRP, interleukin-6, ferritin, LDH, D-dimers, and total fibrinogen had weaker associations with COVID-19 disease severity (all ROC curves with lower AUCs). Thus, GPF may be a useful inflammatory marker of COVID-19 respiratory disease severity.

Keywords: Biomarkers; COVID-19; Disease progression; Fibrinogen; Respiratory distress syndrome.

 
Back
Top Bottom